Hanahan, D., & Weinberg, R. A. (2000). The hallmark of cancer. Cell, 100, 57–70.
Hanahan, D., & Weinberg, R. A. (2011). Hallmark of cancer: the next generation. Cell, 144, 646–674.
Hanahan, D. (2020). Hallmarks of cancer: new dimensions. Cancer Discovery, 12, 31–46.
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discovery, 9, 837–851.
Perekatt, A. O., Shah, P. P., Cheung, S., Jariwala, N., Wu, A., & Ghandi, V. (2018). SMAD4 suppresses WNT-driven dedifferentiation and oncogenesis in the differentiated gut epithelium. Cancer Research, 78, 4878–4890.
Ordonez-Moran, P., Dafflon, C., Imajo, M., Nidshida, E., & Hudsken, J. (2015). HOXA5 counteracts stem cell traits by initiating WNT signaling in colorectal cancer. Cancer Cell, 28, 815–829.
Goding, C. R., & Arnheiter. (2019). MITF – the first 25 years. Genes and Development, 33, 983–1007.
Shah, M., Bhoumik, A., Goel, V., Dewing, A., Breitweiser, W., Kluger, H., et al. (2010). A role for ATF2 in regulating MITF and melanoma development. PlosOne Genet, 6, e1001258.
Saghafinia, S., Homicsko, K., Di Domenico, A., Wullschleger, S., Perren, A., Marinoni, I., et al. (2021). Cancer cells retrace a stepwise differentiation program during malignant progression. Cancer Discovery, 11, 2638–2657.
De The, H. (2018). Differentiation therapy revisited. Nature Reviews. Cancer, 18, 117–127.
Boes, M., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., et al. (2014). Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood, 123, 1341–1352.
Kaufmann CK, Mosimann C, Fan ZP, Yang S, Thomas AJ Ablain J et al. (2016) Zebrafish melanoma model reveals emergence of neural creast identity during melanoma initiation. Science,351:aad2197
Saha, S. K., Parachoniale, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., et al. (2014). Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer. Nature, 513, 110–114.
Krah, N. M., Narayanan, S. M., Yugawa, D. E., Straley, J., Wright, C. V. E., MacDonald, R. J., et al. (2019). Prevention and reversion of pancreatic tumorigenesis through a differentiation based mechanism. Developmental Cell, 50, 744–754.
Shi, G., Di Renzo, D., Qu, C., Barney, D., Miley, D., & Konieczny, S. F. (2013). Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene, 32, 1950–1958.
Krah, N. M., De La, O. J. P., Swift, G. H., Hoang, C. Q., Millet, S. G., Chen Pan, F., et al. (2015). The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma. eLife, 4, e07125.
Ma, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoove, E., Chen, C.-C., et al. (2017). SOX2 promotes linage plasticities and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science, 355, 84–88.
Nagano, T., Tachihara, M., & Nishimura, Y. (2018). Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells, 7, 212.
Brabletz, T., Kalluri, R., Nieto, A., & Weinberg, R. A. (2018). EMT in cancer. Nature Reviews. Cancer, 18, 128–134.
Guarino, M., Rubino, B., & Ballabio, G. (2007). The role of epithelial-mesenchymal transition in cancer pathology. Pathology, 39, 305–318.
Acloque, H., Thierry, J. P., & Nieto, M. A. (2008). The physiology and pathology of the EMT. EMBO Reports, 9, 322–326.
Migault, M., Sapkota, S., & Bracken, C. P. (2022). Transcriptional and post-translational control of epithelial-mesenchymal plasticity: why so many regulators? Cellular and Molecular Life Sciences, 79, 182.
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stwemmler, M. P. (2021). Dynamic EMT: a multi-tool for tumor progression. The EMBO Journal, 40, e108647.
Fedele, M., Sgarra, R., Battista, S., Cerchia, L., & Manfioletti, G. (2022). The epithelial-mesenchymal transition at the crossroads between metabolism and tumor progression. International Journal of Molecular Sciences, 23, 800.
Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cummings, H., et al. (2012). INTERFEROMEv2.0: an updated database of annotated interferon regulated genes. Nucleic Acids Research, 41, D1040–D1046.
Olmelda, D., Moreno-Bueno, G., Flores, J. M., Fabra, A., Portillo, F., & Cano, A. (2007). SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Research, 67, 11721–11731.
Krebs, A. M., Mitschke, J., Losada, M. L., Schmalhofer, O., Berries, M., Busch, H., et al. (2017). The EMT-activator ZEB1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology, 19, 518–529.
Denecker, G., Vandamme, N., Akay, O., Koludrovic, D., Taminau, J., Lemeire, K., et al. (2014). Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death and Differentiation, 21, 1250–1261.
Tang, X., Sui, X., Weng, L., & Liu, Y. (2021). SNAIL1: linking tumor metastasis to immune evasion. Frontiers in Immunology, 12, 724200.
Vuletic, A., Matinovic, K. M., Miletic, N. T., Zoidakis, J., Castellvi-Bel, S., & Cavic, M. (2021). Cross-talk between tumor cells undergoing epithelial to mesenchymal transitionand natural killer cells in tumor microenvironment in colorectalcancer. Frontiers in Cell and Developmental Biology, 9, 750022.
Greaves, D., & Calle, Y. (2022). Epithelial mesenchymal transition and associated invasive adhesions in solid and haematological tumours. Cells, 11, 649.
Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Peer, J., et al. (1999). Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. The American Journal of Pathology, 155, 739–752.
Döme, B., Hendrix, M. J. C., Paku, S., Tovari, J., & Tímár, J. (2007). Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. The American Journal of Pathology, 170, 1–15.
Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003). Vasculogenic mimicry and tumour cell plasticity: lessons from melanoma. Nature Reviews. Cancer, 3, 411–421.
Bittner, M., Meltzer, P., Chen, Y., Jang, Y., Seftor, E. A., Hendrix, M. J. C., et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression: shifting from a continous spectrum to distinct biological entries. Nature, 406, 536–540.
Postovit, L.-M., Margaryan, N. V., Seftor, E. A., Kirschmann, D. A., Lipavsky, A., Wheaton, W. W., et al. (2008). Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggresive cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 105, 4329–4334.
Folberg, R., & Maniotis, A. J. (2004). Vasculogenic mimicry. APMIS, 112, 508–525.
Seftor, R. E. B., Hess, E. A., Seftor, E. A., Kirschmann, D. A., Hardy, K. M., Margaryan, N. V., & Hendrix, M. J. C. (2012). Tumor cell vasculogenic mimicry. From controversy to therapeutic promise. The American Journal of Pathology, 181, 1115–1125.
Hess, A. R., Margaryan, N. V., Seftor, E. A., & Hendrix, M. J. C. (2007). Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Developmental Dynamics, 236, 3283–3296.
Hess, A. R., Postovit, L.-M., Margaryan, N. V., Seftor, E. A., Schneider, G. B., Seftor, R. E. B., Nickoloff, B. J., & Hendrix, M. J. C. (2005). Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Research, 65, 9851–9860.
Sun, T., Zhao, N., Zhao, X. L., Gu, Q., Zhang, S. W., Che, N., et al. (2010). Expression and functional significance of TWIST1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Cancer Research, 51, 545–556.
Wang, J. Y., Sun, T., Zhao, X. L., Zhang, S. W., Zhan, D. F., Gu, Q., et al. (2008). Functional significance of VEGF-A in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biology & Therapy, 7, 758–766.
Strizzi, L., Hardy, K. M., Seftor, E. A., Costa, F. F., Kirschmann, D. A., Seftor, R. E. B., et al. (2009). Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Research, 69, 7131–7134.
Hardy, K. M., Kirschmann, D. A., Seftor, E. A., Margaryan, N. V., Postovit, L. M., Strizzi, L., & Hendrix, M. J. C. (2010). Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Research, 70, 10340–10350.
Wei, X., Chen, Y., Jiang, X., Peng, M., Liu, Y., Mo, Y., et al. (2021). Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Molecular Cancer, 20, 7.
留言 (0)